Butamirate Citrate is commonly used to help with symptomatic relief for non-productive cough. It is relevant across conditions presenting with disruptive symptom manifestations, including acute bronchitis, tracheitis, and the symptomatic management of Whooping Cough (Pertussis).

Targeting the Dry, Persistent, and Irritant Symptom Cluster

The medication is commonly used to help with symptomatic relief for cough that is characteristically dry, persistent, and non-productive, a common manifestation in conditions involving inflammatory or irritative processes. It supports the management of irritation and the constant, non-beneficial urge to cough, assisting patients across relevant age groups.

Easing Distress and Supporting Functional Stability

Панатус is applied when symptoms related to heightened physiological activity interfere with daily functioning and sleep. By addressing symptoms related to heightened physiological activity, it provides supportive relief that helps ease the overall symptom burden of night-time episodes, supporting general well-being during symptomatic phases. It is also relevant in clinical settings that involve acute or unstable symptom patterns, such as before and after surgical procedures.

---

Quick Fact: Symptomatic Relief for Non-Productive Cough The medication is commonly used when short-term symptomatic assistance is needed to moderate irritant symptoms that interfere with daily functioning and sleep, which may cause physical distress.

Regulatory References

1. Ethiopian Food and Drug Authority (EFDA) Summary of Product Characteristics

Official Regulatory Eligibility for Панатус (Butamirate Citrate)

The official regulatory documentation for Панатус defines eligibility status based on patient characteristics and clinical state, establishing who is permitted to use the medicine, who is restricted, and who is strictly prohibited.

Populations for Whom Use is Contraindicated: Use is formally contraindicated in children under 3 years of age and during the first trimester of pregnancy. The medicine is prohibited for patients with a known hypersensitivity to the active substance or excipients, as well as those with specific metabolic disorders (e.g., hereditary fructose intolerance) when using certain formulations.

Restricted and Conditional Use: The label specifies that use must be avoided in patients simultaneously taking expectorants to prevent the risk of mucus accumulation. Use during the second and third trimesters of pregnancy is restricted and permitted only with caution and when essential. Use in lactating women is generally not recommended. Furthermore, patients with impaired renal or hepatic function are conditional use populations, as official data on safety are lacking. Use is established for adults, adolescents, and children from 3 to 12 years of age.

Interactions with Other Medicines and Products

Official regulatory documents define specific limitations for the co-administration of this product (Butamirate Citrate) with certain categories of medicinal products and substances. These limitations are based on documented pharmacodynamic and pharmacokinetic interactions that necessitate restrictions on use.

Key Interaction Restrictions:

Interacting Product Category	Official Regulatory Constraint
Expectorants (Mucus-clearing agents)	Concomitant use must be avoided.
CNS Depressants (Hypnotics, tranquilizers, neuroleptics, etc.)	Use is not recommended.
Ethanol (Alcohol)	Use is not recommended.
Strong Enzyme Inhibitors	Use should not occur together.
Narrow Therapeutic Index Drugs	Use should not occur together.

Simultaneous administration with Expectorants is explicitly restricted because the cough-suppressing action can inhibit the natural clearance of mucus from the respiratory tract. This stagnation increases the risk of serious complications, including bronchospasm and respiratory tract infections.

Co-administration with Ethanol or other CNS Depressants may lead to an additive central nervous system depression, which necessitates a warning against combined use. The prohibition against combining with Strong Enzyme Inhibitors and Narrow Therapeutic Index Drugs reflects the possibility of altering the plasma concentrations of either Butamirate or the co-administered drug, respectively, leading to an increased risk of adverse exposure.

Central Targeting of the Cough Centre

The central action of Butamirate involves a direct inhibitory action on the Cough Centre located in the medulla oblongata of the brainstem. The molecule acts as a modulator, engaging specific binding sites (such as the Dextromethorphan-Binding Site) to suppress the excitability of these central neurons. This targeted action dampens the neural signaling of the tussigenic reflex arc, directly reducing the central efferent signals.

---

Modulation of Airway Smooth Muscle Tone

The peripheral action of the molecule is exerted through a spasmolytic action on the bronchial smooth muscle. This modulation relaxes the tension in the airways, resulting in bronchodilation and a reduction in mechanical resistance. This physiological change modulates afferent signaling from the airways, thereby coordinating with the central inhibition of the cough centre.

---

Mechanistic Constraints on Physiological Efficacy

The mechanism is constrained when high levels of bronchial secretions are present. Suppressing the reflex prevents the mechanical assistance required for mucociliary clearance. Consequently, the mechanism is physiologically constrained in conditions where the expulsion of accumulated material is the necessary physiological response.

How to Use Панатус: Administration Guidelines

The use of Butamirate Citrate follows specific instructions dictating its route, form, and dosing schedules. This medicine is for oral administration and is available as a liquid solution/syrup and in tablet form. Dosing regimens are specified according to the patient's age and are calculated using the active ingredient concentration, typically 7.5 mg per 5 mL of solution. The syrup formulation must be accurately measured using a calibrated device before ingestion.

---

Dosing by Age Group (Syrup/Solution)

Age Group	Single Dose (mg/mL)	Frequency
Children (6–12 years)	15 mg / 10 mL	Three times per day
Adolescents (>12 years)	22.5 mg / 15 mL	Three times per day
Adults	22.5 mg / 15 mL	Up to four times per day

---

Administration Scope and Constraints

The administration protocol establishes a daily regimen administered multiple times throughout the day, with the maximum dose for adults being 90 mg (four daily doses of 22.5 mg). This medicine is intended for short-term symptomatic management, and instructions limit the duration of continuous administration to a maximum of seven days. Furthermore, guidelines advise against the simultaneous use of this medicine with expectorants (substances that encourage mucus production), as this is a key procedural restriction defining the medicine’s use pattern.

Research Evidence / Overview of Studies for Панатус (Butamirate Citrate)

This overview summarizes the available research base for Панатус (Butamirate Citrate), focusing strictly on the structure of clinical trials and the patterns of findings reported in official and peer-reviewed sources. This information is descriptive only and does not provide medical advice, dosing instructions, or recommendations.

---

Evidence for Use in Symptom Changes Related to Dry, Irritative Cough

Research exploring Панатус has focused primarily on the evaluation of symptom changes in conditions characterized by acute or episodic dry, non-productive cough, such as those associated with seasonal respiratory disorders or acute bronchitis. Studies for this area have typically been designed as short-term Randomized Controlled Trials (RCTs) or controlled comparative studies. The studies evaluated patient-reported outcomes describing episodic or acute changes in cough and outcomes related to symptom intensity or variability.

Focus on Study Outcomes and Comparisons

The studies examined outcomes related to the measured change in cough severity and the change in the frequency of cough episodes over short, defined time intervals. Functional outcomes reflecting daily functioning, specifically whether the cough impacted night-time sleep or rest, were also evaluated.

In comparative research scenarios, Butamirate was studied against other antitussive agents. Findings described measured changes in cough symptoms that were documented during the observation of groups receiving comparator treatments in short-term studies. However, some highly specific, placebo-controlled research exploring the drug's activity on the cough reflex sensitivity did not result in a distinction from the measured change observed in the placebo group in the primary endpoint.

---

Duration of Studies and Long-Term Follow-up

The majority of the research describing symptom patterns comes from trials designed to observe responses over defined time intervals, with typical follow-up durations being short-term, often ranging between three and five days of treatment. Because the research primarily focuses on acute, short-duration episodes, there is limited information for long-term outcomes or the consistency of measured effects if treatment extends beyond the acute phase. Long-term effects are not fully established in the core efficacy evidence.

---

Evidence Gaps and Research Limitations

While a body of research exists, the overall evidence landscape includes certain limitations and areas where certainty remains low. The evidence includes studies where the quality of research methodology was inconsistent across the total body of work. Specifically, some data supporting initial authorization did not always meet contemporary standards for methodological rigor. Furthermore, in some research scenarios, such as those involving specialized populations (e.g., cough related to cancer) or specific diagnostic sub-groups, the data show patterns related to very modest sample sizes. These research limitations indicate that findings describe group patterns reflective of the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly.

Key Studies & References A Randomized, Open Label, Crossover Pharmacokinetic And Dose Proportionality Study Of Butamirate Citrate At Single Doses of 22.5, 45, 67.5 and 90 mg In Healthy Adult Volunteers (PK study abstract)

Common questions about Панатус (FAQ)

---

Q: What is the right dose of Панатус syrup for a 4-year-old child?

A: Official regulatory documents define the appropriate single dose based on the patient's age. For children in this age range, a specific, reduced single dose is defined compared to the dosage for older children and adolescents. Detailed dosing schedules are found in the Administration Guidelines section.

---

Q: How quickly does Панатус start working after taking it?

A: Studies and official product information indicate that the active component is absorbed rapidly following oral administration. The medicine's main active metabolite generally reaches its maximum concentration in the blood in approximately 1.5 hours, which is a measure of how quickly the medicine is absorbed.

---

Q: Can I drive or operate heavy machinery while taking Панатус?

A: Official safety documents indicate that because the medicine may cause side effects such as drowsiness or dizziness, caution is required when engaging in activities such as driving or operating machinery. Individuals should refer to the warnings provided in the patient information leaflet.

---

Q: What happens if I forget to take a dose of Панатус?

A: Official product information suggests that if a scheduled dose is missed, it should be skipped completely. The patient should then take the next scheduled dose at the regular time. It is advised not to take a double dose to make up for the one that was missed.

---

Q: What should I do if I accidentally take too much Панатус (Overdose)?

A: If there is a suspicion of an overdose, official guidance advises seeking medical attention immediately. Symptoms of overdose may include various effects such as dizziness, vomiting, and drowsiness. Medical attention would be required for management, as supportive treatments are typically utilized.

---

Q: How should I store Панатус tablets, and is it different from the syrup?

A: The general storage requirement for the medicine is a temperature not exceeding 30 C. Specific instructions for the tablet formulation, including details like shelf life and protection from light or moisture, are provided in the product labeling and should be referenced.

The storage and disposal instructions for Панатус (Butamirate Citrate) are defined strictly by regulatory labeling to ensure product stability and environmental safety.

Official Storage Requirements

The medicine must be stored at temperatures not exceeding 30°C. It is mandatory that the product be actively protected from light and moisture. For the oral syrup, the shelf life after the bottle is first opened is typically six months.

Child Safety and Disposal

It is required to keep this medicine out of the sight and reach of children at all times. Regarding disposal, unused or expired product and any waste material must not be thrown away via wastewater or household waste. Instead, the medicine should be disposed of in accordance with local pharmaceutical requirements.